Projected Cost-beneficial Impact of the Selective Cytopheretic Device in Pediatric Acute Kidney Injury Requiring Kidney Replacement Therapy
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Rationale & Objective
The Selective Cytopheretic Device for Pediatrics (SCD-PED) is a cell-directed extracorporeal therapy approved by US FDA for pediatric patients with acute kidney injury (AKI) due to sepsis or a septic condition, requiring antibiotics and continuous renal replacement therapy (CRRT). This study aimed to estimate hospitalization costs and outcomes of SCD-PED therapy by leveraging the Kids’ Inpatient Database (KID) and SCD-PED studies.
Study Design
Publicly available hospitalization cost data were combined with clinical metrics from prior SCD-PED studies to assess the impact of SCD-PED on inpatient hospital costs among pediatric patients receiving CRRT.
Setting & Population
The SCD-PED was evaluated in two multicenter pediatric studies, involving 16 and 6 patients, respectively. Pediatric patients with AKI and multi-organ dysfunction receiving CRRT as part of standard care were included. The KID subset comprised hospitalizations with CRRT, a length of stay (LOS) up to 60 days, mortality and severity level 4, an AKI diagnosis, and total parenteral nutrition (TPN) procedures.
Interventions
Patients received SCD-PED therapy for up to 7 or 10 days or until CRRT termination.
Outcomes
Outcomes analyzed included hospital LOS, mortality, vasopressor use, mechanical ventilation, sepsis diagnosis, number of SCD-PED devices used, and hospitalization cost estimates.
Model, Perspective, & Timeframe
A regression-based economic cost model compared costs between SCD-PED therapy and theoretical controls, adjusted to 2024 US dollars.
Results
Modeled hospitalization costs were $457,092 in the KID cohort and $389,451 in the ppCRRT cohort. Median hospital LOS was lower in the SCD-PED group (28 days vs. 31 days), resulting in lower estimated costs ($320,304) and an estimated savings of $69,146 per hospitalization.
Limitations
Small sample sizes and single-arm design with no prospective control arm. Reported costs are estimates based on models.
Conclusions
The SCD-PED shows potential for survival benefit and cost-benefit in critically ill children with AKI requiring CRRT, including those with sepsis.
